Glass maker Schott predicts enough vials to go around for COVID-19 vaccines
By Ludwig Burger FRANKFURT (Reuters) - Germany's unlisted Schott AG, the world's biggest supplier of speciality glass for medical bottles and syringes, said on Wednesday it did not see any shortage of vials for bottling COVID-19 vaccines. Drugmakers last year warned of limited supplies of vials to bottle future COVID-19 vaccines, but Schott said at the time that their rush to secure supplies early risked making matters worse
COVID-19 vaccines" src="https://images.firstpost.com/wp-content/uploads/reuters/01-2021/21/2021-01-20T164343Z_1_LYNXMPEH0J18J_RTROPTP_2_HEALTH-CORONAVIRUS-ASPEN-PHARMACARE-VACCINE.jpg" alt="Glass maker Schott predicts enough vials to go around for COVID19 vaccines" width="300" height="225" />
By Ludwig Burger
FRANKFURT (Reuters) - Germany's unlisted Schott AG, the world's biggest supplier of speciality glass for medical bottles and syringes, said on Wednesday it did not see any shortage of vials for bottling COVID-19 vaccines.
Drugmakers last year warned of limited supplies of vials to bottle future COVID-19 vaccines, but Schott said at the time that their rush to secure supplies early risked making matters worse.
Schott, whose founder Otto Schott invented heavy-duty borosilicate glass in the 1890s, delivered 110 million vials for COVID-19 vaccines during the second half of last year and was now scheduled to clear an order backlog of 600 million vials for that purpose well into 2022.
While this translates into "what looks like a gigantic" number of roughly 6 billion vaccine doses to be filled, those outstanding orders only amount to roughly one tenth of Schott's annual total output of medical glass vials, Chief Executive Frank Heinricht told Reuters.
The risk that vaccine developers in earlier stages might be blocking vial capacities at the expense of suppliers that have already won regulatory approval was now low, he added.
"Customers are ordering only to the extent that they actually build up their own production capacities," said Heinricht.
"We seek reassurance that orders are not placed to build early reserves, so that all firms that really need (vials) for filling can be served," he added.
Schott, with 2.2 billion euros ($2.7 billion) in annual sales, competes in the market for borosilicate glass tubes with Nippon Electric Glass, Nipro and Corning Inc.
It also makes the finished bottles, or vials, with peers in a more fragmented market including France's SGD Pharma, Germany's Gerresheimer and Italy's Stevanato Group.
($1 = 0.8263 euros)
(Additional reporting by Patricia Weiss, editing by Thomas Escritt and Emelia Sithole-Matarise)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply
By John McCrank NEW YORK (Reuters) - Robinhood, the online brokerage used by many retail traders to pile in to heavily shorted stocks like GameStop Corp, has made an ambitious push into loaning out its clients' shares to short sellers as it expands its business. The broker had $1.9 billion in shares loaned out as of Dec. 31, nearly three times the $674 million a year earlier, and it was permitted to lend out $4.6 billion worth of securities under margin agreements, around five times bigger than the prior year, according to an annual regulatory filing late on Monday
By Pete Schroeder and Chris Prentice WASHINGTON (Reuters) - U.S. President Joe Biden's pick to head a key market regulator promised on Tuesday a thorough review of issues raised by the GameStop Corp stock frenzy and suggested companies may have to disclose their potential risks from climate change